Online Pharmaceutical

On March 9, at the American College of Cardiology Scientific Sessions in New Orleans, investigators presented details of their studies with rimonabant (trade name: Acomplia) – the first of a new class of drugs (selective CB1 blockers) aimed at helping with weight loss and smoking cessation. CB1 blockers act on the endocannabinoid system (the EC system), a natural system that modulates the body’s energy balance and nicotine dependence. An over-stimulated EC system is thought to play a role in obesity and in tobacco dependence, and CB1 blockers are supposed to reduce this overstimulation. In a press release 3 weeks ago, the makers of rimonabant (Sanofi-Synthelabo,) indicated that the studies were favorable.

Data from two studies with rimonabant were reported this week. In the first, called the Stratus-US study, the drug’s effect on smoking cessation was evaluated. In this study, 787 smokers (average of 23 cigarettes per day) were randomized to receive either placebo, or rimonabant in doses of either 5 mg or 20 mg per day. The patients received the study drugs for 10 weeks. They were permitted to continue smoking for the first 2 weeks, but were instructed to attempt to quit smoking on Day 15. The number of patients who had not smoked during the last 4 weeks of the 10 week period were tabulated. Of patients who took 20 mg of rimonabant, 36% had quit smoking. Of patients who took either placebo or 5 mg rimonabant, only 20% successfully quit. Further, of those patients who quit smoking, the ones taking either placebo or 5 mg rimonabant gained 84% more weight than those taking 20 mg rimonabant. Thus, rimonabant at 20 mg per day significantly increased the rate of successfully quitting smoking, and also greatly reduced post-smoking-cessation weight gain.

In the second study (the RIO-Lipids study,) 1036 patients who were either overweight or obese and who had blood lipid disorderswere also randomized to one of three groups (placebo vs. 5 mg/day or 20 mg/day rimonabant). After 1 year of treatment, patients receiving 20 mg rimonabant lost an average of about 20 pounds of weight, compared to 5 pounds for patients on placebo. Further, patients receiving 20 mg rimonabant had significant improvements (compared to placebo) in waist circumference, HDL levels, triglyceride levels, CRP levels, and insulin sensitivity. For patients with metabolic syndrome at baseline (which included about 50% of the study population), half of those taking 20 mg rimonabant no longer had metabolic syndromeat the end of the study.

Smartness of an individual can only be gauzed by the action he or she takes to get out of a problem. Whatever may be the complexity of such a problem, only a smart individual can get out of it with flying colours. Obesity is one such problem which is really complex. It needs a lot or determination, willpower and patience if someone is thinking to get out of it. Even individuals who are smart in other spheres of life come to their wits end, to get out of obesity.

Obesity can result from excessive intake of food, lack of physical activities, lack of knowledge on balanced diet and genetic factors etc. Obesity can also be visible as a result of side effect of some certain kind of medications. Obesity is considered as a disease by the medical fraternity as it may give rise to future health risks like – heart ailments, diabetes, prostate cancer, high blood pressure, and hypertension etc. Hence, it is important to get rid of obesity when time is left.

Acomplia is a diet pill is a sympathomimetic amine and is known as �anorexigenic’ or �anorectic’ drug too. This diet pill stimulates the central nervous system and its periphery thus helps in increasing heart rate and blood pressure. This increase in blood pressure and heart rate helps one decrease his or her appetite. Acomplia is a short term appetite suppressant to be used in tandem with controlled diet and exercises. As Acomplia is a diet supplement it cannot directly help one get out of obesity rather it helps in supplementing the process of weight loss through exercises.

When assessing weight problems, the medical profession refer to our Body Mass Index. A healthy index is anywhere between eighteen and a half and twenty five. If it’s any higher, then we’re too heavy for our height. Furthermore we’re defined as obese and morbidly obese respectively if we rise above first thirty and then forty.

A simple calculation can be done to work out your BMI. Make a note of how heavy you are in kilograms and how tall you are in metres. Your BMI calculation is then done by taking your height and squaring it, and dividing that by your weight.

For instance – say you’re 1.55 metres tall and you weigh 78 kilos, your index would be 32.5. Clearly that result shows some different eating and exercise habits are needed, as a figure over 30 is categorised as obese.

We can’t lose weight if we continue to consume foods highly saturated in fats and sugars (save for the odd treat now and again!). The fat that’s already stored in our bodies will only be used up if we put less fuel (food) into our system. By eating healthy food we will make that system more efficient.

Acomplia Rimonabant a wonder poly pill developed by world famous french pharmaceuticals. Rimonabant sold under brand name Acomplia in Europe and as Zimulti in USA. Rimonabant Acomplia is developed to treat obesity and is approved by European Union in June 2006. Rimonabant Acomplia zimulti is not yet approved for smoking cessation treatment. You can Buy Acomplia Rimonabant online with prescription. Rimonabant Acomplia Zimulti diet pill causes weight reduction, a customary dosage of Rimonabant Zimulti is considered similar to that of Acomplia dosage which is 20mg.Rimonabant Acomplia is to be swallowed in one gulp with a full glass of water. Rimonabant Acomplia zimulti diet pill is to be consumed in conjunction with a low-calorie diet and regular exercises.

Acomplia Weight Loss

Acomplia (Rimonabant) .The medical society has approved the Acomplia that is one of most pioneering pharmaceuticals in present times. The US Drug Maker Sanofi-Synthelabo develops this weight loss formulation. People also know it as the anti-Marijuana and supplies munchies. It is used to block the capability of receiving the munchies indications. It is a good supplement used for weight loss and works quite effectively.

Owing to its popularity, people would like to know how it works in our body, firstly you must know that it is very first CB1 cannabinoid receptor blocker that is found in our brain. By blocking it, you don’t feel any hunger and it starts your losing weight. It has been well tested in laboratories and found more effective than other medicines to control your weight. But it is quite necessary for you to consult a doctor before taking it in order to escape from any kind of its side effects.